<info type="DiseaseOrPhenotypicFeature">Delirium</info> in a patient with <info type="ChemicalEntity">toxic flecainide</info> plasma concentrations: the role of a <info type="ChemicalEntity">pharmacokinetic drug interaction</info> with <info type="ChemicalEntity">paroxetine</info>.

OBJECTIVE: To describe a case of <info type="ChemicalEntity">flecainide</info>-induced <info type="DiseaseOrPhenotypicFeature">delirium</info> associated with a <info type="ChemicalEntity">pharmacokinetic drug interaction</info> with <info type="ChemicalEntity">paroxetine</info>. CASE SUMMARY: A <info type="OrganismTaxon">69-year-old white female</info> presented to the emergency department with a history of <info type="DiseaseOrPhenotypicFeature">confusion</info> and <info type="DiseaseOrPhenotypicFeature">paranoia</info> over the past several days. On admission the patient was taking <info type="ChemicalEntity">carvedilol</info> <info type="ChemicalEntity">12 mg</info> twice daily, <info type="ChemicalEntity">warfarin</info> <info type="ChemicalEntity">2 mg/day</info>, <info type="ChemicalEntity">folic acid</info> <info type="ChemicalEntity">1 mg/day</info>, <info type="ChemicalEntity">levothyroxine</info> <info type="ChemicalEntity">100 microg/day</info>, <info type="ChemicalEntity">pantoprazole</info> <info type="ChemicalEntity">40 mg/day</info>, <info type="ChemicalEntity">paroxetine</info> <info type="ChemicalEntity">40 mg/day</info>, and <info type="ChemicalEntity">flecainide</info> <info type="ChemicalEntity">100 mg</info> twice daily. <info type="ChemicalEntity">Flecainide</info> had been started 2 weeks prior for <info type="DiseaseOrPhenotypicFeature">atrial fibrillation</info>. Laboratory test findings on admission were notable only for a <info type="ChemicalEntity">flecainide</info> plasma concentration of <info type="ChemicalEntity">1360 microg/L</info> (reference range <info type="ChemicalEntity">200-1000</info>). A <info type="ChemicalEntity">metabolic drug interaction</info> between <info type="ChemicalEntity">flecainide</info> and <info type="ChemicalEntity">paroxetine</info>, which the patient had been taking for more than 5 years, was considered. <info type="ChemicalEntity">Paroxetine</info> was discontinued and the dose of <info type="ChemicalEntity">flecainide</info> was reduced to <info type="ChemicalEntity">50 mg</info> twice daily. Her <info type="DiseaseOrPhenotypicFeature">delirium</info> resolved 3 days later. DISCUSSION: <info type="ChemicalEntity">Flecainide</info> and pharmacologically similar agents that interact with <info type="GeneOrGeneProduct">sodium channels</info> may cause <info type="DiseaseOrPhenotypicFeature">delirium</info> in susceptible patients. A <info type="ChemicalEntity">MEDLINE</info> search (1966-January 2009) revealed one in vivo <info type="ChemicalEntity">pharmacokinetic study</info> on the interaction between <info type="ChemicalEntity">flecainide</info>, a <info type="GeneOrGeneProduct">CYP2D6 substrate</info>, and <info type="ChemicalEntity">paroxetine</info>, a <info type="GeneOrGeneProduct">CYP2D6 inhibitor</info>, as well as 3 case reports of <info type="ChemicalEntity">flecainide</info>-induced <info type="DiseaseOrPhenotypicFeature">delirium</info>. According to the <info type="GeneOrGeneProduct">Naranjo probability scale</info>, <info type="ChemicalEntity">flecainide</info> was the probable cause of the patient's <info type="DiseaseOrPhenotypicFeature">delirium</info>; the <info type="GeneOrGeneProduct">Horn Drug Interaction Probability Scale</info> indicates a possible <info type="ChemicalEntity">pharmacokinetic drug interaction</info> between <info type="ChemicalEntity">flecainide</info> and <info type="ChemicalEntity">paroxetine</info>. CONCLUSIONS: <info type="ChemicalEntity">Supratherapeutic flecainide</info> plasma concentrations may cause <info type="DiseaseOrPhenotypicFeature">delirium</info>. Because toxicity may occur when <info type="ChemicalEntity">flecainide</info> is prescribed with <info type="ChemicalEntity">paroxetine</info> and other potent <info type="GeneOrGeneProduct">CYP2D6 inhibitors</info>, <info type="ChemicalEntity">flecainide</info> plasma concentrations should be monitored closely with commencement of <info type="GeneOrGeneProduct">CYP2D6 inhibitors</info>.